High expression of miR‑21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma

Yi,Peng  Sheng; Li,Jian Shui

doi:10.3892/mco.2018.1603

High expression of miR‑21 is not a predictor of poor prognosis in all patients with hepatocellular carcinoma

Authors:
- Peng Sheng Yi
- Jian Shui Li
View Affiliations

Affiliations: Department of Hepatobiliary and Pancreatic Disease, Institute of General Surgery, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan 637000, P.R. China
Published online on: April 3, 2018 https://doi.org/10.3892/mco.2018.1603
Pages: 733-739
Copyright: © Yi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNA (miR)‑21 has been identified as a novel biomarker of hepatocellular carcinoma (HCC). However, the prognostic value of miR‑21 expression in HCC remains controversial. The aim of the present study was to investigate the value of high expression of miR‑21 in predicting the prognosis of HCC. Following a search through the PubMed, Science Citation Index, EMBASE and CNKI databases, a total of 9 studies investigating the expression of miR‑21 in HCC and the association between high expression of miR‑21 and prognosis of HCC were identified. It was observed that high expression of miR‑21 was not associated with poor overall survival of all patients with HCC (P=0.52). However, high expression of miR‑21 was found to be correlated with poor prognosis of HCC patients undergoing curative resection (hazard ratio = 2.36; P<0.01). It was also demonstrated that high expression of miR‑21 was correlated with tumor size >5 cm [odds ratio (OR)=1.53; P=0.04], venous invasion (OR=4.86; P=0.01), TNM stage (OR=3.44; P<0.01) and liver cirrhosis (OR=2.12; P=0.03). It was concluded that miR‑21 cannot be considered as a factor complementary to α‑fetoprotein, microvascular invasion and advanced tumor stage in predicting the prognosis of all HCC patients. Higher expression of miR‑21 may be a promising biomarker associated with certain clinicopathological characteristics of HCC, such as tumor size, venous invasion, TNM stage and liver cirrhosis.

View Figures

View References

1	Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW and Kuo WH: Current systemic treatment of hepatocellular carcinoma: A review of the literature. World J Hepatol. 7:1412–1420. 2015. View Article : Google Scholar : PubMed/NCBI
2	Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, Neri D, Boccagni P, Srsen N, D'Amico F, et al: Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol. 44:723–731. 2006. View Article : Google Scholar : PubMed/NCBI
3	Yi PS, Zhang M and Xu MQ: Management of the middle hepatic vein in right lobe living donor liver transplantation: A meta-analysis. J Huazhong Univ Sci Technolog Med Sci. 35:600–605. 2015. View Article : Google Scholar : PubMed/NCBI
4	Yi PS, Zhang M, Zhao JT and Xu MQ: Liver resection for intermediate hepatocellular carcinoma. World J Hepatol. 8:607–615. 2016. View Article : Google Scholar : PubMed/NCBI
5	Montani F and Bianchi F: Circulating cancer biomarkers: The macro-revolution of the micro-rna. EBioMedicine. 5:4–6. 2016. View Article : Google Scholar : PubMed/NCBI
6	Chou CH, Chang NW, Shrestha S, Hsu SD, Lin YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, et al: miRTarBase 2016: Updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res. 44(D1): D239–D247. 2016. View Article : Google Scholar : PubMed/NCBI
7	Pfeffer SR, Yang CH and Pfeffer LM: The role of mir-21 in cancer. Drug Dev Res. 76:270–277. 2015. View Article : Google Scholar : PubMed/NCBI
8	Tomimaru Y, Eguchi H, Nagano H, Wada H, Tomokuni A, Kobayashi S, Marubashi S, Takeda Y, Tanemura M, Umeshita K, et al: MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer. 103:1617–1626. 2010. View Article : Google Scholar : PubMed/NCBI
9	Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, Tanemura M, Tomokuni A, Takemasa I, Umeshita K, et al: Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 56:167–175. 2012. View Article : Google Scholar : PubMed/NCBI
10	Karakatsanis A, Papaconstantinou I, Gazouli M, Lyberopoulou A, Polymeneas G and Voros D: Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog. 52:297–303. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wang Y, Gao X, Wei F, Zhang X, Yu J, Zhao H, Sun Q, Yan F, Yan C, Li H and Ren X: Diagnostic and prognostic value of circulating miR-21 for cancer: A systematic review and meta-analysis. Gene. 533:389–397. 2014. View Article : Google Scholar : PubMed/NCBI
12	Yan SR, Liu ZJ, Yu S and Bao YX: Investigation of the value of miR-21 in the diagnosis of early stage HCC and its prognosis: A meta-analysis. Genet Mol Res. 14:11573–11586. 2015. View Article : Google Scholar : PubMed/NCBI
13	Stang A: Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 25:603–605. 2010. View Article : Google Scholar : PubMed/NCBI
14	Lo CK, Mertz D and Loeb M: Newcastle-Ottawa Scale: Comparing reviewers' to authors' assessments. BMC Med Res Methodol. 14:452014. View Article : Google Scholar : PubMed/NCBI
15	Tierney JF, Stewart LA, Ghersi D, Burdett S and Sydes MR: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
16	Zhou X, Wang X, Huang Z, Wang J, Zhu W, Shu Y and Liu P: Prognostic value of miR-21 in various cancers: An updating meta-analysis. PLoS One. 9:e1024132014. View Article : Google Scholar : PubMed/NCBI
17	Juskeviciute E, Dippold RP, Antony AN, Swarup A, Vadigepalli R and Hoek JB: Inhibition of miR-21 rescues liver regeneration after partial hepatectomy in ethanol-fed rats. Am J Physiol Gastrointest Liver Physiol. 311:G794–G806. 2016. View Article : Google Scholar : PubMed/NCBI
18	Chen X, Song M, Chen W, Dimitrova-Shumkovska J, Zhao Y, Cao Y, Song Y, Yang W, Wang F, Xiang Y and Yang C: Microrna-21 contributes to liver regeneration by targeting pten. Med Sci Monit. 22:83–91. 2016. View Article : Google Scholar : PubMed/NCBI
19	Hu S, Tao R, Wang S, Wang C, Zhao X, Zhao H, Li L, Zhu S, He Y, Jiang X and Gao Y: MicroRNA-21 promotes cell proliferation in human hepatocellular carcinoma partly by targeting HEPN1. Tumour Biol. 36:5467–5472. 2015. View Article : Google Scholar : PubMed/NCBI
20	Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST and Patel T: MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 133:647–658. 2007. View Article : Google Scholar : PubMed/NCBI
21	Bao L, Yan Y, Xu C, Ji W, Shen S, Xu G, Zeng Y, Sun B, Qian H, Chen L, et al: MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways. Cancer Lett. 337:226–236. 2013. View Article : Google Scholar : PubMed/NCBI
22	He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S and Sun X: MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget. 6:28867–28881. 2015. View Article : Google Scholar : PubMed/NCBI
23	Zhu Q, Wang Z, Hu Y, Li J, Li X, Zhou L and Huang Y: miR-21 promotes migration and invasion by the miR-21-PDCD4-AP-1 feedback loop in human hepatocellular carcinoma. Oncol Rep. 27:1660–1668. 2012.PubMed/NCBI
24	Qiu X, Dong S, Qiao F, Lu S, Song Y, Lao Y, Li Y, Zeng T, Hu J, Zhang L, et al: HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma. Oncogene. 32:3296–3305. 2013. View Article : Google Scholar : PubMed/NCBI
25	Wang X, Zhang J, Zhou L, Lu P, Zheng ZG, Sun W, Wang JL, Yang XS, Li XL, Xia N, et al: Significance of serum microRNA-21 in diagnosis of hepatocellular carcinoma (HCC): Clinical analyses of patients and an HCC rat model. Int J Clin Exp Pathol. 8:1466–1478. 2015.PubMed/NCBI
26	Huang CS, Yu W, Cui H, Wang YJ, Zhang L, Han F and Huang T: Increased expression of miR-21 predicts poor prognosis in patients with hepatocellular carcinoma. Int J Clin Exp Pathol. 8:7234–7238. 2015.PubMed/NCBI
27	Wang WY, Zhang HF, Wang L, Ma YP, Gao F, Zhang SJ and Wang LC: miR-21 expression predicts prognosis in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 38:715–719. 2014. View Article : Google Scholar : PubMed/NCBI
28	Wang H, Hou L, Li A, Duan Y, Gao H and Song X: Expression of serum exosomal microRNA-21 in human hepatocellular carcinoma. Biomed Res Int. 2014:8648942014.PubMed/NCBI
29	Liu M, Liu J, Wang L, Wu H, Zhou C, Zhu H, Xu N and Xie Y: Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival. PLoS One. 9:e1093472014. View Article : Google Scholar : PubMed/NCBI
30	Gyöngyösi B, Végh É, Járay B, Székely E, Fassan M, Bodoky G, Schaff Z and Kiss A: Pretreatment microrna level and outcome in sorafenib-treated hepatocellular carcinoma. J Histochem Cytochem. 62:547–555. 2014. View Article : Google Scholar : PubMed/NCBI